Skip to main content

Stephanie Gaillard

Adjunct Assistant Professor in the Department of Medicine
Medicine, Medical Oncology
DUMC 3079, Durham, NC 27710
DUMC Box 3079, Durham, NC 27710

Overview


Dr. Stéphanie Gaillard is an Assistant Professor in Medical Oncology at the Duke Cancer Institute. Dr. Gaillard is board certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. At Duke, she focuses on treating patients with gynecologic malignancies and conducts basic science and clinical research. Dr. Gaillard’s laboratory research focuses on elucidating the biology of ovarian cancer, especially metabolic changes in the development of ovarian tumors, and mechanisms of resistance to chemotherapy. Her clinical research interests center on the development of novel therapeutic strategies for the treatment of ovarian cancer through early phase clinical trials. In addition to the Ovarian Cancer Research Fund Liz Tilberis Grant, Dr. Gaillard has received a Department of Defense Breast Cancer Research Program pre-doctoral research award and a Conquer Cancer Foundation Young Investigator Award.

Current Appointments & Affiliations


Adjunct Assistant Professor in the Department of Medicine · 2017 - Present Medicine, Medical Oncology, Medicine

Recent Publications


NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY: Cervical Cancer, Version 2.2026

Journal Article Jnccn Journal of the National Comprehensive Cancer Network · December 1, 2025 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cervical Cancer provide diagnostic workup, staging, and various treatment recommendations for cervical cancer based on clinical and surgical staging. This selection from the NCCN Guide ... Full text Cite

Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement.

Journal Article Gynecologic oncology · November 2025 Interstitial lung disease (ILD) is a potentially serious and sometimes fatal complication of targeted therapies, including antibody-drug conjugates and immunotherapies, in gynecologic oncology. Risk factors include pre-existing lung disease, advanced age a ... Full text Cite
View All Publications